Following the report, Marex's stock dropped 6.2%, closing at $35.31 on heavy trading volume. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Marex Group plc due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit set for December 8, 2025 [3][8]. Group 1: Allegations Against Marex - The complaint alleges that Marex and its executives made false and misleading statements, failing to disclose significant issues such as selling over-the-counter financial instruments to itself and inconsistencies in financial statements [6]. - A report by NINGI Research accused Marex of a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions, including a fabricated receivable of $17 million and nearly $1 billion in concealed derivatives exposure [7]. - Following the release of the report, Marex's stock experienced a significant decline of 6.2%, closing at $35.31 [9]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased Marex securities between May 16, 2024, and August 5, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [2]. - The role of lead plaintiff in the class action lawsuit is designated for the investor with the largest financial interest, who will oversee the litigation on behalf of the class [10]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Marex's conduct [11].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Marex Group plc due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a federal class action by December 8, 2025 [2][5]. Group 1: Allegations Against Marex - The complaint alleges that Marex and its executives made false or misleading statements and failed to disclose critical information, including the sale of over-the-counter financial instruments to itself and inconsistencies in financial statements [5]. - Specific allegations include a multi-year accounting scheme involving off-balance-sheet entities, fictitious transactions, and misleading disclosures to hide losses and inflate profits, with examples such as a $17 million fabricated receivable and nearly $1 billion in concealed derivatives exposure [6]. - Following the release of a damaging report by NINGI Research, Marex's stock experienced a significant decline of 6.2%, closing at $35.31 [7]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased Marex securities between May 16, 2024, and August 5, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1]. - The role of lead plaintiff in the class action is designated to the investor with the largest financial interest, who will oversee the litigation on behalf of the class [8]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Marex's conduct [9].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Marex To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Marex between May 16, 2024 and August 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - November 13, 2025) - Faruqi & ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Marex Group plc due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by December 8, 2025 [4]. Group 1: Allegations Against Marex - The complaint alleges that Marex and its executives made false and misleading statements and failed to disclose critical information, including the sale of over-the-counter financial instruments to itself and inconsistencies in financial statements [6]. - Specific allegations include a multi-year accounting scheme involving off-balance-sheet entities, fictitious transactions, and misleading disclosures to hide losses and inflate profits, with examples such as a $17 million fabricated receivable and nearly $1 billion in concealed derivatives exposure [7]. - Following the release of a report by NINGI Research, Marex's stock dropped 6.2%, closing at $35.31 on heavy trading volume [8]. Group 2: Legal Proceedings and Investor Actions - Investors who suffered losses exceeding $10,000 in Marex between May 16, 2024, and August 5, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights [1]. - The role of lead plaintiff in the class action is designated to the investor with the largest financial interest who is typical of class members, with options for other members to either move to serve as lead plaintiff or remain absent [9]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Marex's conduct [10].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Marex Group plc due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by December 8, 2025 [3][5]. Summary by Sections Legal Investigation - Faruqi & Faruqi, LLP is a national securities law firm that has recovered hundreds of millions of dollars for investors since its inception in 1995 [4]. - The firm is encouraging investors who purchased Marex securities between May 16, 2024, and August 5, 2025, to discuss their legal rights [3][9]. Allegations Against Marex - The complaint against Marex alleges violations of federal securities laws, including making false or misleading statements and failing to disclose critical financial inconsistencies [5]. - Specific allegations include the sale of over-the-counter financial instruments to itself, inconsistencies in financial statements, and misleading positive statements about the company's operations and prospects [5]. NINGI Research Report - A report released by NINGI Research on August 5, 2025, accused Marex of a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions to hide losses and inflate profits [6]. - The report highlighted a fabricated receivable of $17 million, inflated subsidiary profits, and nearly $1 billion in concealed derivatives exposure [6]. Market Reaction - Following the release of the NINGI Research report, Marex's stock experienced a decline of 6.2%, closing at $35.31 with heavy trading volume [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Marex Group plc due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status by December 8, 2025 [1][3]. Group 1: Allegations Against Marex - The complaint alleges that Marex and its executives made false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements [3]. - A report from NINGI Research accused Marex of a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions, including a fabricated receivable of $17 million and nearly $1 billion in concealed derivatives exposure [4]. - Following the release of the report, Marex's stock experienced a decline of 6.2%, closing at $35.31 on heavy trading volume [5]. Group 2: Legal Proceedings and Investor Actions - The lead plaintiff in the class action lawsuit will be the investor with the largest financial interest who is adequate and typical of class members, and any member of the class may move to serve as lead plaintiff [6]. - Faruqi & Faruqi encourages individuals with information regarding Marex's conduct, including whistleblowers and former employees, to contact the firm [6].

Core Viewpoint - Marex Group plc is facing a class action lawsuit due to allegations of engaging in a multi-year accounting scheme that misled investors about its financial health and risk exposure [3]. Group 1: Legal Action - The Portnoy Law Firm is advising Marex Group plc investors to join a class action lawsuit for those who purchased securities between May 16, 2024, and August 5, 2025 [1]. - Investors have until December 8, 2025, to file a lead plaintiff motion [1]. - The law firm offers complimentary case evaluations and options for investors to recover losses [2]. Group 2: Financial Allegations - A report by NINGI Research claims that Marex has been involved in a deceptive accounting scheme, utilizing off-balance-sheet entities and fictitious transactions to hide losses and inflate profits [3]. - Following the release of this report, Marex's stock price dropped by $2.33, or 6.19%, closing at $35.31 per share on August 5, 2025 [3]. Group 3: Law Firm Background - The Portnoy Law Firm has a history of recovering over $5.5 billion for investors affected by corporate wrongdoing [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Marex Group plc due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by December 8, 2025 [4][6]. Group 1: Allegations Against Marex - The complaint alleges that Marex and its executives made false and misleading statements and failed to disclose critical information, including the sale of over-the-counter financial instruments to itself and inconsistencies in financial statements [6]. - Specific allegations include a multi-year accounting scheme involving off-balance-sheet entities, fictitious transactions, and misleading disclosures to hide losses and inflate profits, with examples such as a $17 million fabricated receivable and nearly $1 billion in concealed derivatives exposure [7]. - Following the release of a report by NINGI Research, Marex's stock experienced a significant drop of 6.2%, closing at $35.31 on heavy trading volume [8]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased Marex securities between May 16, 2024, and August 5, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1][10]. - The role of lead plaintiff in the class action is designated to the investor with the largest financial interest who is typical of class members, with the option for any member to move the court to serve as lead plaintiff [9].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Marex Group plc due to allegations of securities law violations, with a deadline for investors to seek lead plaintiff status by December 8, 2025 [1][3]. Group 1: Allegations Against Marex - The complaint alleges that Marex and its executives made false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements [3]. - A report from NINGI Research accused Marex of a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions, including a fabricated receivable of $17 million and nearly $1 billion in concealed derivatives exposure [4]. - Following the release of the report, Marex's stock experienced a significant drop of 6.2%, closing at $35.31 [5]. Group 2: Legal Proceedings - The lead plaintiff in the class action will be the investor with the largest financial interest who is adequate and typical of class members, with options for other members to participate or remain absent [6]. - Faruqi & Faruqi encourages anyone with information regarding Marex's conduct to come forward, including whistleblowers and former employees [6].